Aurora Cannabis Inc. (TSE:ACB – Get Free Report)’s stock price hit a new 52-week low during trading on Monday . The stock traded as low as C$3.74 and last traded at C$3.76, with a volume of 313521 shares. The stock had previously closed at C$3.86.
Analysts Set New Price Targets
ACB has been the subject of several analyst reports. Canaccord Genuity Group decreased their price objective on Aurora Cannabis from C$6.50 to C$5.00 and set a “buy” rating for the company in a report on Tuesday, June 30th. TD reduced their price target on Aurora Cannabis from C$10.00 to C$8.00 and set a “buy” rating for the company in a research report on Friday, June 12th. Three investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of C$7.17.
Check Out Our Latest Stock Report on Aurora Cannabis
Aurora Cannabis Stock Performance
Aurora Cannabis (TSE:ACB – Get Free Report) last announced its quarterly earnings results on Thursday, June 11th. The company reported C($0.99) EPS for the quarter. Aurora Cannabis had a negative net margin of 12.13% and a negative return on equity of 7.25%. The firm had revenue of C$38.01 million during the quarter. On average, analysts predict that Aurora Cannabis Inc. will post -0.22 earnings per share for the current year.
Aurora Cannabis Company Profile
Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael ’71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.
See Also
- Five stocks we like better than Aurora Cannabis
- Meta Platforms Stock Rises as Muse Spark 1.1 AI Model Debuts
- Why Welltower’s Growth Story Might Outrun Its Rich Valuation
- One Short- and One Long-Term ETF for Quantum Computing Bulls
- The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
Receive News & Ratings for Aurora Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurora Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.
